A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Clinical trial NCT03112603 · COMPLETED
Trial details
- NCT number
- NCT03112603
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-29
- Primary completion
- 2020-05-08
- Enrollment
- 330
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.